(E)-3-(2,3-dihydro-1H-indol-7-yl)-2-(phosphonomethyl)prop-2-enoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(2,3-dihydro-1H-indol-7-yl)-2-(phosphonomethyl)prop-2-enoic acid
• 化学式: C₁₂H₁₄NO₅P
• 分子量: 283.22
• InChiKey: HHUQVUAPLRCDPG-POHAHGRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] SMALL MOLECULE ANTAGONISTS OF PF4 CONTAINING ULTRA LARGE COMPLEXES<br/>[FR] ANTAGONISTES À PETITES MOLÉCULES DE PF4 CONTENANT DES COMPLEXES ULTRA-LARGES
  申请人：TRUSTEES OF THE UNIVERSITY OF PENSYLVANIA

  公开号：WO2013142328A1

  公开（公告）日：2013-09-26

  Methods for preventing formation of or disrupting PF4 tetramers are provided. The compounds useful in such methods bind to a PF4 tetramer, dimer, or monomer. The compounds are also useful for preventing formation of or disrupting ultra-large complexes containing a PF4 tetramer and a glycosaminoglycan, and thus have utility toward preventing or treating medical conditions related to the formation of PF4 tetramers, such as HITT and atherosclerosis and toward correcting a platelet imbalance, preventing a decrease in platelet production and increasing high density lipoproteins in a subject. Also provided are compositions and kits containing these compounds and optional medications which cause the formation of PF4 tetramers, and/or medications which disrupt PF4 tetramers. [Formula I]